OncoZenge: SAFE approval secured - Redeye
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen

Aktieanalys

OncoZenge: SAFE approval secured - Redeye

{newsItem.title}

Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.2m investment agreement with Yangtian Pharma, marking a critical step in securing funding for the pivotal phase III trial of BupiZenge. We see this as an important milestone that improves the company’s financial outlook and supports continued operational progress.

Länk till analysen i sin helhet: https://www.redeye.se/research/1116331/oncozenge-safe-approval-secured?utm_source=finwire&utm_medium=RSS

Nyheter om OncoZenge

Läses av andra just nu

Om aktien OncoZenge

Senaste nytt